阅读说明：本技术 一种预防宠物2型糖尿病的复合微生态制剂及其应用 (Compound microecological preparation for preventing type 2 diabetes of pets and application thereof ) 是由 德艳艳 廖洪 龙谭 于 2019-10-22 设计创作，主要内容包括：本发明公开了一种预防宠物2型糖尿病的复合微生态制剂及其应用,包括益生菌混合物,余量用低聚木糖和菊粉补足,所述低聚木糖和菊粉的添加质量比为1:1；所述益生菌混合物包括动物双歧杆菌、干酪乳杆菌、副干酪乳杆菌、嗜热双歧杆菌和长双歧杆菌,所述动物双歧杆菌、干酪乳杆菌、副干酪乳杆菌、嗜热双歧杆菌和长双歧杆菌的数量比为1:1:1:1:1。本发明使用的复合微生态制剂所包含的动物双歧杆菌、干酪乳杆菌、副干酪乳杆菌、嗜热双歧杆菌、长双歧杆菌,菊粉和低聚木糖,协同作用增加肠道益生菌,调节肠道菌群平衡,主要用于预防宠物T2DM的发生,同时具有改善肠道菌群,减少慢性炎症的产生,起到促进健康,提高机体免疫力的功能,预防和改善胰岛素抵抗,从而起到预防宠物2型糖尿病的作用。(The invention discloses a composite microecological preparation for preventing type 2 diabetes of pets and application thereof, wherein the preparation comprises a probiotic mixture, and the balance of probiotic mixture is complemented by xylooligosaccharide and inulin, wherein the addition mass ratio of the xylooligosaccharide to the inulin is 1: 1; the probiotic mixture comprises bifidobacterium animalis, lactobacillus casei, lactobacillus paracasei, bifidobacterium thermophilum and bifidobacterium longum, and the number ratio of the bifidobacterium animalis to the lactobacillus casei to the lactobacillus paracasei to the bifidobacterium thermophilum to the bifidobacterium longum is 1:1:1:1: 1. The bifidobacterium animalis, the lactobacillus casei, the lactobacillus paracasei, the bifidobacterium thermophilum, the bifidobacterium longum, the inulin and the xylooligosaccharide contained in the composite microecological preparation have synergistic effects of increasing intestinal probiotics and regulating the balance of intestinal flora, are mainly used for preventing T2DM of pets, and simultaneously have the functions of improving the intestinal flora, reducing the generation of chronic inflammation, promoting health, improving the immunity of organisms and preventing and improving insulin resistance, thereby having the function of preventing type 2 diabetes of pets.)

1. The compound microecological preparation for preventing type 2 diabetes of pets is characterized in that: comprises a probiotic mixture, and the balance of the probiotic mixture is complemented by xylo-oligosaccharide and inulin, wherein the adding mass ratio of the xylo-oligosaccharide to the inulin is 1: 1; the probiotic mixture comprises bifidobacterium animalis, lactobacillus casei, lactobacillus paracasei, bifidobacterium thermophilum and bifidobacterium longum, and the number ratio of the bifidobacterium animalis to the lactobacillus casei to the lactobacillus paracasei to the bifidobacterium thermophilum to the bifidobacterium longum is 1:1:1:1: 1.

2. The complex microecological formulation according to claim 1, wherein the inhibitor comprises a compound of formula i: the number of viable bacteria of Bifidobacterium animalis strain is not less than 2.0 × 10¹⁰CFU/g, the viable count of lactobacillus casei is more than or equal to 2.0 multiplied by 10¹⁰CFU/g, the viable count of lactobacillus paracasei is more than or equal to 2.0 multiplied by 10¹⁰CFU/g, the number of viable bifidobacterium thermophilum is more than or equal to 2.0 multiplied by 10¹⁰CFU/g, number of viable bacteria of Bifidobacterium longum is not less than 2.0 × 10¹⁰CFU/g。

3. The complex microecological formulation according to claim 1, wherein the inhibitor comprises a compound of formula i: the survival rate of the lactobacillus casei and the lactobacillus paracasei is more than 60 percent when the lactobacillus casei and the lactobacillus paracasei are cultured in simulated gastric acid with the pH value of 3.0 for 2 hours.

4. The complex microecological formulation according to claim 1, wherein the inhibitor comprises a compound of formula i: the survival rate of the animal bifidobacterium, the thermophilic bifidobacterium and the bifidobacterium longum is more than 50 percent when the animal bifidobacterium, the thermophilic bifidobacterium and the bifidobacterium longum are cultured in simulated gastric acid with the pH value of 3.0 for 2 hours.

5. The complex microecological formulation according to claim 1, wherein the inhibitor comprises a compound of formula i: the survival rates of the strains of the lactobacillus casei, the lactobacillus paracasei, the bifidobacterium animalis, the bifidobacterium thermophilum and the bifidobacterium longum are all more than 20 percent when the lactobacillus casei, the lactobacillus paracasei, the bifidobacterium animalis, the bifidobacterium thermophilum and the bifidobacterium longum are cultured in 0.2 percent of No. 3 bile salt for 2 hours.

6. The use of the complex probiotic for the prevention of type 2 diabetes in pets according to claim 1, characterized in that: the compound microecological preparation is used for preventing type 2 diabetes caused by obesity of pet dogs and cats.

Technical Field

The invention relates to the technical field of medicines, and particularly relates to a composite microecological preparation for preventing type 2 diabetes of pets and application thereof.

Background

Diabetes is a metabolic disorder disease caused by lack of insulin, and is easy to occur to obese middle-aged and old-aged dogs and cats. The diabetes of pets is classified into type 1, type 2 and type 3. Type 1 diabetes is also called insulin-dependent diabetes, and diseased dogs and cats usually cannot secrete insulin because pancreatic beta cells are dysplastic or damaged, and need to be treated with insulin for a lifetime. Type 2 diabetes is also called non-insulin dependent diabetes mellitus, and the impaired sensitivity and reduced number of receptors on insulin target cells usually cause insulin resistance and cell dysfunction in sick dogs and cats, resulting in relative insulin deficiency. Type 2 diabetes is most likely to occur in cats. Type 3 diabetes, also known as secondary diabetes, often results in insulin antagonism and glucose intolerance due to damage to the islets from inflammation and surgery among other known diseases. Type 2 diabetes is caused by obesity due to lack of exercise and excessive food intake of pets, besides heredity. Research shows that the intestinal flora of diabetics has increased abundance of harmful bacteria such as Enterobacteriaceae bacteria and the like, and decreased abundance of beneficial bacteria such as bifidobacteria, lactic acid bacteria and the like. Thus regulating intestinal flora can improve blood sugar level of diabetic patients. At present, probiotics or prebiotics are adopted to improve and correct intestinal flora of diabetics, and clinical tests have achieved certain effects. However, at present, there is no probiotic for pets for preventing or improving type 2 diabetes.

Research shows that the increase of the expression level of the chronic inflammatory factor is one of the causes of type 2 diabetes caused by insulin resistance, and the intestinal flora in obese hosts is remarkably changed and is related to the generation of the chronic inflammation, so that the prevention of diabetes and the improvement of blood sugar of obese pets are extremely important.

Disclosure of Invention

The invention aims to provide a compound microecological preparation for preventing type 2 diabetes of pets, which can increase intestinal probiotics, regulate the balance of intestinal flora, prevent and improve insulin resistance, and an application thereof.

In order to achieve the purpose, the invention provides the following technical scheme: the compound microecological preparation for preventing type 2 diabetes of pets is characterized in that: comprises a probiotic mixture, and the balance of the probiotic mixture is complemented by xylo-oligosaccharide and inulin, wherein the adding mass ratio of the xylo-oligosaccharide to the inulin is 1: 1; the probiotic mixture comprises bifidobacterium animalis, lactobacillus casei, lactobacillus paracasei, bifidobacterium thermophilum and bifidobacterium longum, and the number ratio of the bifidobacterium animalis to the lactobacillus casei to the lactobacillus paracasei to the bifidobacterium thermophilum to the bifidobacterium longum is 1:1:1:1: 1.

Further, the viable count of the animal bifidobacterium strain is more than or equal to 2.0 multiplied by 10¹⁰CFU/g, the viable count of lactobacillus casei is more than or equal to 2.0 multiplied by 10¹⁰CFU/g, the viable count of lactobacillus paracasei is more than or equal to 2.0 multiplied by 10¹⁰CFU/g, the number of viable bifidobacterium thermophilum is more than or equal to 2.0 multiplied by 10¹⁰CFU/g, number of viable bacteria of Bifidobacterium longum is not less than 2.0 × 10¹⁰CFU/g。

Further, the survival rate of the lactobacillus casei and the lactobacillus paracasei is more than 60 percent when the lactobacillus casei and the lactobacillus paracasei are cultured in simulated gastric acid with the pH value of 3.0 for 2 hours.

Further, the survival rate of the animal bifidobacterium, the thermophilic bifidobacterium and the bifidobacterium longum is more than 50 percent when the animal bifidobacterium, the thermophilic bifidobacterium and the bifidobacterium longum are cultured in simulated gastric acid with the pH value of 3.0 for 2 hours.

Furthermore, the survival rates of the strains of the lactobacillus casei, the lactobacillus paracasei, the bifidobacterium animalis, the bifidobacterium thermophilum and the bifidobacterium longum are all more than 20 percent when the lactobacillus casei, the lactobacillus paracasei, the bifidobacterium animalis, the bifidobacterium thermophilum and the bifidobacterium longum are cultured in 0.2 percent of No. 3 bile salt for 2 hours.

The invention also aims to provide an application of the composite microecological preparation for preventing the type 2 diabetes of pets, and the composite microecological preparation is used for preventing the type 2 diabetes of pets caused by obesity.

Compared with the prior art, the invention has the beneficial effects that: the bifidobacterium animalis, the lactobacillus casei, the lactobacillus paracasei, the bifidobacterium thermophilum, the bifidobacterium longum, the inulin and the xylooligosaccharide contained in the composite microecological preparation have synergistic effects of increasing intestinal probiotics and regulating the balance of intestinal flora, are mainly used for preventing T2DM of pets, and simultaneously have the functions of improving the intestinal flora, reducing the generation of chronic inflammation, promoting health, improving the immunity of organisms and preventing and improving insulin resistance, thereby having the function of preventing type 2 diabetes of pets.

Detailed Description

The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.